Jaguar Health Business Summary

Jaguar Health, Inc. (JAGX) is a commercial-stage pharmaceutical company that generates revenue through the development and commercialization of plant-based, non-opioid prescription medicines for gastrointestinal (GI) disorders. Its business model has recently evolved into a high-leverage licensing and manufacturing framework, highlighted by a 2026 agreement with Future Pak that provided an $18 million upfront payment for U.S. rights to its lead products, Mytesi and Canalevia-CA1. The company operates through two primary segments: Human Health, focused on rare diseases like Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS), and Animal Health, targeting chemotherapy-induced diarrhea in dogs. Jaguar competes against major pharmaceutical firms such as Lexicon Pharmaceuticals and Bausch Health, as well as clinical-stage peers like BioVie and Quince Therapeutics. Relative to these competitors, Jaguar distinguishes itself by leveraging its proprietary library of sustainably derived rainforest plants to address niche orphan indications, positioning itself as a specialized R&D and manufacturing hub rather than a broad-market commercial distributor. The company was founded by Lisa Conte, who serves as President and CEO and brings over three decades of experience in ethnobotanical drug discovery, including her previous leadership at Shaman Pharmaceuticals. The executive team includes Chief Financial Officer Carol Lizak and Chief Scientific Officer Dr. Pravin Chaturvedi, whose background includes senior roles in drug development and clinical strategy for GI-focused therapeutics. Other key leadership figures include Chief of Staff Jonathan Wolin and Chief Manufacturing Officer David Sesin, who manages the company’s production of crofelemer as a profit-generating service for its licensees. Jaguar’s governance is overseen by a board led by Independent Chairman James Bochnowski, a co-founder of Delphi Ventures. The company has maintained strategic financial relationships with notable investors such as Triton Funds LLC and Streeterville Capital, which have provided bridge financing and debt restructuring to support Jaguar’s clinical progression toward multiple NDA filings targeted for late 2026.